WO2007150074A3 - Compositions comprising nanoparticulate naproxen and controlled release hydrocodone - Google Patents

Compositions comprising nanoparticulate naproxen and controlled release hydrocodone Download PDF

Info

Publication number
WO2007150074A3
WO2007150074A3 PCT/US2007/072052 US2007072052W WO2007150074A3 WO 2007150074 A3 WO2007150074 A3 WO 2007150074A3 US 2007072052 W US2007072052 W US 2007072052W WO 2007150074 A3 WO2007150074 A3 WO 2007150074A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydrocodone
compositions
composition
component
controlled release
Prior art date
Application number
PCT/US2007/072052
Other languages
French (fr)
Other versions
WO2007150074A2 (en
Inventor
Paul Stark
John Devane
Niall Fanning
Gary Liversidge
Scott Jenkins
Gurvinder Singh-Rekhi
Original Assignee
Elan Pharma Int Ltd
Paul Stark
John Devane
Niall Fanning
Gary Liversidge
Scott Jenkins
Gurvinder Singh-Rekhi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd, Paul Stark, John Devane, Niall Fanning, Gary Liversidge, Scott Jenkins, Gurvinder Singh-Rekhi filed Critical Elan Pharma Int Ltd
Priority to EP07799011A priority Critical patent/EP2032137A2/en
Priority to BRPI0713447-9A priority patent/BRPI0713447A2/en
Priority to MX2008016223A priority patent/MX2008016223A/en
Priority to CA002660649A priority patent/CA2660649A1/en
Priority to JP2009516756A priority patent/JP2009541359A/en
Priority to AU2007260821A priority patent/AU2007260821B2/en
Publication of WO2007150074A2 publication Critical patent/WO2007150074A2/en
Publication of WO2007150074A3 publication Critical patent/WO2007150074A3/en
Priority to IL196065A priority patent/IL196065A0/en
Priority to NO20090158A priority patent/NO20090158L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to a compositions comprising a nanoparticulate naproxen composition in combination with a multiparticulate modified release hydrocodone composition that, upon administration to a patient, delivers a hydrocodone in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of hydrocodone - comprising particles and the at least one subsequent component comprising a second population of hydrocodone-comprising particles, wherein the combination of the components exhibit a bimodal or multimodal release profile. The invention also relates to a solid oral dosage form comprising such a combination composition.
PCT/US2007/072052 2006-06-23 2007-06-25 Compositions comprising nanoparticulate naproxen and controlled release hydrocodone WO2007150074A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP07799011A EP2032137A2 (en) 2006-06-23 2007-06-25 Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
BRPI0713447-9A BRPI0713447A2 (en) 2006-06-23 2007-06-25 solid oral dosage form composition, and, method for treating pain
MX2008016223A MX2008016223A (en) 2006-06-23 2007-06-25 Compositions comprising nanoparticulate naproxen and controlled release hydrocodone.
CA002660649A CA2660649A1 (en) 2006-06-23 2007-06-25 Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
JP2009516756A JP2009541359A (en) 2006-06-23 2007-06-25 Composition comprising nanoparticulate naproxen and controlled release hydrocodone
AU2007260821A AU2007260821B2 (en) 2006-06-23 2007-06-25 Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
IL196065A IL196065A0 (en) 2006-06-23 2008-12-18 Compositions comrising nanoparticulate naproxen and controlled release hydrocodone
NO20090158A NO20090158L (en) 2006-06-23 2009-01-12 Composition comprising naproxen nanoparticles and controlled release hydrocarbon

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81588506P 2006-06-23 2006-06-23
US60/815,885 2006-06-23

Publications (2)

Publication Number Publication Date
WO2007150074A2 WO2007150074A2 (en) 2007-12-27
WO2007150074A3 true WO2007150074A3 (en) 2008-04-10

Family

ID=38834446

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/072052 WO2007150074A2 (en) 2006-06-23 2007-06-25 Compositions comprising nanoparticulate naproxen and controlled release hydrocodone

Country Status (12)

Country Link
EP (1) EP2032137A2 (en)
JP (1) JP2009541359A (en)
KR (1) KR20090024284A (en)
CN (1) CN101484170A (en)
AU (1) AU2007260821B2 (en)
BR (1) BRPI0713447A2 (en)
CA (1) CA2660649A1 (en)
IL (1) IL196065A0 (en)
MX (1) MX2008016223A (en)
NO (1) NO20090158L (en)
WO (1) WO2007150074A2 (en)
ZA (1) ZA200810221B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
ES2360102T3 (en) 2003-03-26 2011-05-31 Egalet A/S SYSTEM FOR CONTROLLED RELEASE OF MORPHINE.
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
ES2643291T3 (en) 2010-12-22 2017-11-22 Purdue Pharma L.P. Controlled release dosage forms with inviolable closure coated
CA2822769C (en) 2010-12-23 2016-10-04 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
KR101794032B1 (en) 2011-09-21 2017-11-07 (주)바이오시네틱스 Method for preparing nanoparticles
EP2877161A1 (en) 2012-07-06 2015-06-03 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
KR101840526B1 (en) 2013-02-05 2018-03-20 퍼듀 퍼머 엘피 Tamper resistant pharmaceutical formulations
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
CN112500694B (en) * 2020-12-04 2022-03-29 东莞威赢高尔夫用品有限公司 Electronic equipment veneer material and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US20030129237A1 (en) * 1998-11-02 2003-07-10 Devane John G. Multiparticulate modified release composition
US20050031691A1 (en) * 2002-09-11 2005-02-10 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US20030129237A1 (en) * 1998-11-02 2003-07-10 Devane John G. Multiparticulate modified release composition
US20050031691A1 (en) * 2002-09-11 2005-02-10 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions

Also Published As

Publication number Publication date
KR20090024284A (en) 2009-03-06
NO20090158L (en) 2009-03-20
ZA200810221B (en) 2009-11-25
BRPI0713447A2 (en) 2012-03-13
JP2009541359A (en) 2009-11-26
MX2008016223A (en) 2009-01-19
EP2032137A2 (en) 2009-03-11
WO2007150074A2 (en) 2007-12-27
CA2660649A1 (en) 2007-12-27
IL196065A0 (en) 2009-09-01
CN101484170A (en) 2009-07-15
AU2007260821A1 (en) 2007-12-27
AU2007260821B2 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
WO2007150075A3 (en) Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
WO2007150074A3 (en) Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2006131591A3 (en) An entacapone-containing oral dosage form
WO2010003127A3 (en) Antagonists of prostaglandin d2 receptors
WO2008033351A3 (en) Multimodal abuse resistant and extended release formulations
WO2007109160A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
IL195488A (en) Compounds, pharmaceutical compositions comprising the same and uses thereof
IL196426A (en) Microparticles based on an amphiphilic copolymer, processes for the preparation thereof and pharmaceutical compositions containing the same
WO2009145989A3 (en) Aminoalkylphenyl antagonists of prostaglandin d2 receptors
EP2045251A4 (en) Compound that can inhibit ubc13-uev interactions, pharmaceutical compositions and therapeutic uses
WO2006099514A3 (en) Drug delivery compositions and related methods
IL192967A0 (en) Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
WO2007019439A3 (en) Block copolymer compositions and uses thereof
EP1986702A4 (en) Hyperpolarization methods, systems and compositions
LT2029480T (en) Biologicallly active nanoparticles of a carbonate-substituted hydroxyapatite, process for their preparation and compositions incorporating the same
WO2007109182A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007117556A3 (en) Pharmaceutical compositions and uses thereof
WO2007109201A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007002823A3 (en) Formulations of conjugated estrogens and bazedoxifene
WO2009087634A3 (en) Methods and compositions for oral administration of insulin
WO2010066749A3 (en) Ulipristal acetate tablets
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
WO2009039157A3 (en) Orlistat pharmaceutical formulations

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780023616.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07799011

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007260821

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2660649

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007799011

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2008/016223

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 196065

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2009516756

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007260821

Country of ref document: AU

Date of ref document: 20070625

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097001439

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: RU

ENP Entry into the national phase

Ref document number: PI0713447

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081222